Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.
|NCPE Assessment Process||Complete|
|Rapid review received||20/11/2017|
|Rapid review completed||21/11/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.